European CML Blast Crisis Register

Overview

Multicentric prospective and retrospective register collecting patient with CML blast crisis diagnosed in Germany and Europe

Since the advent of treatment with tyrosine kinase inhibitors (TKI), the incidence of blast crises has significantly decreased. Nevertheless, about 5% of patients diagnosed with chronic myeloid leukemia (CML) will evolve into a blast phase at some point during the course of their disease. Furthermore, despite the advances made in CML treatment, outcome of patients with blast crises are still dismal. Due to the rarity of this condition clinical trials are challenging, and collaboration between researchers both at national and international level is needed to collect a meaningful number of data.

Conditions

Eligibility

Locations (9)

Outcomes

Central Contacts